Trials / Completed
CompletedNCT04812067
A Safety and Efficacy Trial of TTHX1114 in People With CED
A Phase 2 Clinical Trial to Assess the Safety and Observe the Potential Benefit of TTHX1114 Delivered Via Intra-Cameral (IC) Injection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Trefoil Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Expanded access, open label study at a single dose level in patients with CED that in the opinion of the investigators might benefit from TTHX1114
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TTHX1114 | engineered FGF-1 |
Timeline
- Start date
- 2021-11-30
- Primary completion
- 2023-08-29
- Completion
- 2023-10-31
- First posted
- 2021-03-23
- Last updated
- 2023-11-07
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04812067. Inclusion in this directory is not an endorsement.